Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

With this earnings history in mind, recent estimates have been moving higher for Regeneron. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a ...

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

The six were among 40 finalists nationwide in the Regeneron Science Talent Search, the country's most prestigious science ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

The 16 th annual Prix Galien USA Awards Gala ceremony was held in New York City last week, at the American Museum of Natural History. Dr George D. Yancopoulos, Regeneron’s chief scientific ...